Key clinical point: Bleeding rates continue to decline with longer-term emicizumab use in hemophilia A.
Major finding: Mean annualized bleed rates declined to 0.3 after 96 weeks of treatment with emicizumab.
Study details: Analysis of data from the four HAVEN studies involving 399 patients with hemophilia A.
Disclosures: The study was funded by F. Hoffman-La Roche and Chugai Pharmaceutical. Dr. Callaghan declared consultancies, grants, clinical trial involvement, speakers bureau, and shares with the pharmaceutical sector.
Callaghan M et al. 2019 ISTH Congress, Abstract OC 60.2